Tricida Inc

Tricida — Investor Presentation (January 2021)

35 slides from Tricida's investor presentation, Jan 11, 2021

  1. Slide 1: Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease

    Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation January 2021 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs

  3. Slide 3: Our Goals for Veverimer

    3*Veverimer is not yet approved by the FDA First and ONLY FDA-Approved Therapy Significant unmet medical need to treat chronic metabolic acidosis Improve How Patients Feel and Function Enhance physical functioning and physical functioning-related quality of life Disease Modifying Slow CKD progressio

  4. Slide 4: Veverimer Is Being Developed to Treat Metabolic Acidosis and Potentially Slow CKD Progression

    4 August 22, 2020 Complete Response Letter (CRL) Veverimer Is Being Developed to Treat Metabolic Acidosis and Potentially Slow CKD Progression 4Q 2018 Initiated a confirmatory outcomes trial based on accelerated approval guidelines Substantive discussions with the FDA to submit the veverimer NDA thr

  5. Slide 5: Metabolic Acidosis is Commonly Caused by Kidney Disease

    5 Daily Metabolism Metabolic Acidosis is Commonly Caused by Kidney Disease Kraut. Nat Rev Nephrol. 2010;6(5):274; KDIGO Clinical Practice Guidelines 2012. Serum Bicarbonate Levels FallDiseased Kidneys Lose Capacity to Excrete Acid Acid is generated from dietary sources and daily metabolism Diseased

  6. Slide 6: Metabolic Acidosis Is a Serious Condition Needing Treatment

    6 Metabolic Acidosis Is a Serious Condition Harmful Needs to Be Treated 0% 20% 40% 60% 80% 100% Dobre 2013 Tangri 2020 TRCA-301 Tangri 2019 < 3% < 10% 15% < 6% % o f P at ie nt s R ec ei vi ng O ra l A lk al i T he ra pyThe Majority of Patients with Metabolic Acidosis are NOT treated No FDA Approved

  7. Slide 7: Multiple Academic Studies Show Impact of Raising Serum Bicarbonate Levels

    7 Oral alkali Dietary intervention Multiple Academic Studies Show Impact of Raising Serum Bicarbonate Levels Navaneethan et al., CJASN, 2019; 14: 1011-1020. Meta Analysis Shows Slower Decline in eGFR at the End of Study Period with Oral Alkali Supplementation or Reduction of Dietary Acid Intake

  8. Slide 8: Each mEq/L Increase in Serum Bicarbonate Reduces Risk of CKD Progression

    8 Observational Data Show that Each 1 mEq/L Increase in Serum Bicarbonate Reduces the Risk of CKD Progression Tangri et al., NKF SCM, 2018. Data on file. Single Baseline Model Time-Dependent Model Data Source Sunnybrook Hospital, Canada Nationally recognized database, U.S. Sample Size (N) 2,378 24,3

  9. Slide 9: Veverimer: Designed to Bind and Remove Acid in the GI Tract

    Veverimer: Designed to Bind and Remove Acid in the GI Tract to Raise Serum Bicarbonate to Treat Metabolic Acidosis and Slow CKD Progression

  10. Slide 10: Veverimer: Designed to Bind and Remove HCl with High Capacity and Selectivity

    10GI: Gastrointestinal. HCl: Hydrochloric acid. *Veverimer’s maximum theoretical HCl binding capacity is approximately 10 mEq/gram. Excreted, resulting in removal of HCl* Binds protons (H+) and then selectively binds chloride (Cl–) in the GI tract Excretion in Feces O ra l I ng es tio n A ci d B in

  11. Slide 11: Veverimer: Ease of Administration

    11 Veverimer: Ease of Administration* Once-a-day dosing Orally administered as a suspension in water 3 g, 6 g or 9 g dose sizes No observed drug-drug interactions** 2 oz. Water *Targeted profile if approved ** Data on file

  12. Slide 12: Veverimer: Clinical Development Program and Regulatory Path

    Veverimer: Clinical Development Program and Regulatory Path

  13. Slide 13: Veverimer Clinical Program

    13 Veverimer Clinical Program QD = Once daily. Wesson DE et al., Lancet 2019; 393: 1417-27. Wesson DE et al., Lancet 2019; 394: 396-406. Phase 3 Clinical Trials: TRCA-301 / TRCA-301E VALOR-CKD Outcomes Trial Veverimer QD (n~800) Placebo QD (n~800)Tr ea tm en t ~ 4 Y ea rs End of study: 511 primary e

  14. Slide 14: Baseline Disease Characteristics of Subjects Enrolled in TRCA-301

    14 Baseline Disease Characteristics of Subjects Enrolled in TRCA-301 Veverimer N=124 Placebo N=93 Baseline eGFR, mean 29 mL/min/1.73m2 28 mL/min/1.73m2 Baseline serum bicarbonate, mean 17 mEq/L 17 mEq/L Selected Medical History CKD 100% 100% Hypertension 97% 97% Diabetes 61% 70% Left ventricular hyp

  15. Slide 15: Summary of TRCA-301/301E Clinical Trial Results

    15 TRCA-301 Veverimer-Treated Subjects Experienced a Mean Increase from Baseline in Serum Bicarbonate of 4.5 mEq/L Veverimer: Summary of TRCA-301/301E Clinical Trial Results BL: Baseline. W: Week. Error bars: Standard error of the mean. DD50: Death, dialysis or ≥50% reduction in eGFR. Wesson DE et a

  16. Slide 16: Veverimer: TRCA-301/301E Safety Summary

    16 Veverimer: TRCA-301/301E Safety Summary TRCA-301 TRCA-301E Veverimer (n=124) Placebo (n=93) Veverimer (n=114) Placebo (n=82) Discontinued prematurely 4.0% 4.3% 2.6% 9.8% Serious adverse events (none assessed to be related to study drug) 2.4% 2.2% 1.8% 4.9% Gastrointestinal adverse events 16.9% 8.

  17. Slide 17: TRCA-301 and TRCA-301E Trial Results Published in The Lancet

    17 Veverimer: TRCA-301 and TRCA-301E Trial Results Published in The Lancet TRCA-301 Results TRCA-301E Results Wesson DE et al., Lancet 2019; 393: 1417-27. Wesson DE et al., Lancet 2019; 394: 396-406.

  18. Slide 18: VALOR-CKD Confirmatory Outcomes Trial

    VALOR-CKD Confirmatory Outcomes Trial

  19. Slide 19: VALOR-CKD Confirmatory Outcomes Trial

    19 VALOR-CKD Confirmatory Outcomes Trial The trial terminates when the independent blinded Clinical Endpoint Adjudication Committee (CEAC) has positively adjudicated 511 subjects with primary efficacy endpoint events • Two interim analyses are planned for early stopping for efficacy Time-to-event tr

  20. Slide 20: VALOR-CKD Is Adequately Powered for the Observed Treatment Effect

    20 VALOR-CKD Is Adequately Powered for the Treatment Effect Observed in Studies TRCA-301/301E * Post-hoc analysis of change from baseline in serum bicarbonate from TRCA-301/301E showed that the data were not normally distributed. Thus, the between-group difference of the medians, rather than means,

  21. Slide 21: Interim Analyses Are Planned for Early Stopping for Efficacy

    21 Interim Analyses Are Planned for Early Stopping for Efficacy • Interim alpha spending approach: O'Brien-Fleming alpha spending function – Nominal one-sided alpha required for significance at • Interim 1: 0.00004; observed HR will need to be < 0.50 • Interim 2: 0.00151; observed HR will need to be

  22. Slide 22: VALOR-CKD Primary Endpoint Event Tracking

    22 *57 Events VALOR-CKD Primary Endpoint Event Tracking Interim analysis 1: Anticipated 2H 2021 Interim analysis 2: Anticipated mid-2022 Final analysis: Anticipated 2024 VALOR-CKD anticipated event rates based on tracking against event rates observed in previous CKD trials * Data on event rates amon

  23. Slide 23: FDA Regulatory Status

    FDA Regulatory Status IRICIDA

  24. Slide 24: Veverimer Meets Requirements for the Accelerated Approval Program

    24FDA Guidance for Industry—Expedited Programs for Serious Conditions—Drugs and Biologics. Treats a Serious, Life-Threatening Condition Increasing blood bicarbonate may slow progression to ESRD for patients with CKD and metabolic acidosis Meaningful Advantage Over Standard of Care There are no FDA-a

  25. Slide 25: Recent FDA Interactions

    25 Recent FDA Interactions • We received a Complete Response Letter (CRL) in August 2020 indicating that the FDA was seeking additional data from at least one additional adequate and well-controlled study demonstrating the efficacy of veverimer for the treatment of metabolic acidosis associated with

  26. Slide 26: A Formal Dispute Resolution Request Has Been Submitted

    26 A Formal Dispute Resolution Request (FDRR) Has Been Submitted that Focuses on the Narrow Issue of Requisite Magnitude of Benefit • Addressing the issues in the CRL is not a worthwhile endeavor unless Tricida can reach agreement with the FDA that the already-demonstrated magnitude of serum bicarbo

  27. Slide 27: FDRR Status and Potential Next Steps

    27 • FDRR was submitted to the FDA in December 2020 and confirmation of acceptance has been confirmed • Timing and next steps will be dependent upon the Office of New Drug’s (OND’s) decision. Potential scenarios include: – If the FDRR is granted,* the Division would be directed to have label discuss

  28. Slide 28: Veverimer Market Opportunity

    Veverimer Market Opportunity

  29. Slide 29: Concentrated Patient Population Allows Focus on the Nephrology Community

    29 3,000,000 Patients with CKD and metabolic acidosis 1,100,000 Diagnosed patients ~600,000 Nephrologist- treated patients Concentrated Patient Population Allows Focus of Commercial Efforts on the Nephrology Community Focus on nephrologist-treated patients provides initial opportunity for veverimer

  30. Slide 30: Metabolic Acidosis Increases the Cost of Health Care

    30 Analysis of Major Payer Database Shows Metabolic Acidosis Increases the Cost of Health Care Metabolic Acidosis Has a Significant Impact on Health Care Costs Optum® EMR, De-identified electronic medical records 2007–2017. Reaven N, Association of Managed Care Pharmacy; Oct 31, 2019 and ASN Kidney

  31. Slide 31: Intellectual Property, Financial Position and Upcoming Milestones

    Intellectual Property, Financial Position and Upcoming Milestones

  32. Slide 32: Veverimer Patent Protection

    32 • Six already issued Orange Book eligible patents provide patent protection until 2034 • Several pending patent applications United States • Three issued EPO patents providing patent protection until 2034 and a fourth issued patent providing protection until 2035 • Several pending EPO patent appl

  33. Slide 33: Financial Position

    33 Financial Position • ~ $332 million cash, cash equivalents and investments as of December 31, 2020* • Debt includes: • $200 million of 3.50% Convertible Senior Notes due 2027 • $75 million currently drawn under a debt facility with Hercules (final maturity of April 2023) • ~ 50 million total shar

  34. Slide 34: Key Veverimer Milestones

    34*Veverimer is not yet approved by the FDA Key Veverimer Milestones* Obtain clarity on the path forward for resubmitting the veverimer NDA through the Accelerated Approval Program Conduct interim analysis 1 for potential early stopping of VALOR-CKD for efficacy Anticipated completion of trial witho

  35. Slide 35: Thank You

    THANK YOU IRICIDA

Tricida — Investor Presentation (January 2021) on 6ix